Vertaling van "drug approval " (Frans → Nederlands) :

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

Le tiotropium a dès lors reçu le titre de «Drug approval label Category 1S», ce qui signifie qu’il possède les mêmes propriétés thérapeutiques que les autres médicaments commercialisés antérieurement.
Tiotropium kreeg dan ook een “Drug approval label Category 1S”, wat betekent dat het middel dezelfde (“similar”) therapeutische eigenschappen heeft als eerder gecommercialiseerde geneesmiddelen.

En 2010, au moment de l’introduction de la proposition de recherche auprès du KCE, on s’attendait à disposer des résultats des essais cliniques en 2011.On pensait également que le système allait recevoir un « PreMarket Approval » (PMA) de la « Food and Drug Administration » (FDA) américaine.
In 2010, op het moment dat het projectvoorstel bij het KCE ingediend werd, werd verwacht dat de resultaten van de klinische trials in de loop van 2011 beschikbaar zouden zijn en dat het systeem een PreMarket Approval (PMA) zou krijgen van de Amerikaanse Food and Drug Administration (FDA).